National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Adverse Drug Events (ADE) (2)
- (-) Adverse Events (3)
- Blood Clots (1)
- (-) Blood Pressure (3)
- Children/Adolescents (1)
- Chronic Conditions (1)
- Diabetes (1)
- Diagnostic Safety and Quality (1)
- Electronic Health Records (EHRs) (1)
- Health Information Technology (HIT) (1)
- Medical Errors (1)
- Medication (2)
- Medication: Safety (1)
- Patient Safety (1)
- Quality of Care (1)
- Risk (1)
- Sexual Health (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedHorton DB, Xie F, Chen L
Oral glucocorticoids and incident treatment of diabetes mellitus, hypertension, and venous thromboembolism in children.
The purpose of this study was to quantify rates of incident treatment for diabetes mellitus, hypertension, and venous thromboembolism (VTE) associated with oral glucocorticoid exposure in children aged 1-18 years. Participants were identified using US Medicaid claims data and included more than 930,000 children diagnosed with autoimmune diseases or a nonimmune comparator condition. Findings showed strong dose-dependent relationships between current glucocorticoid exposure and all outcomes, suggesting strong relative risks, but low absolute risks, of newly-treated VTE, diabetes, and especially hypertension in children taking high-dose oral glucocorticoids.
AHRQ-funded; HS021110.
Citation: Horton DB, Xie F, Chen L .
Oral glucocorticoids and incident treatment of diabetes mellitus, hypertension, and venous thromboembolism in children.
Am J Epidemiol 2021 Feb 1;190(3):403-12. doi: 10.1093/aje/kwaa197..
Keywords: Children/Adolescents, Diabetes, Chronic Conditions, Blood Clots, Medication: Safety, Medication, Adverse Drug Events (ADE), Adverse Events, Risk, Patient Safety, Blood Pressure
Muldoon MF, Kronish IM, Shimbo D
Of signal and noise: overcoming challenges in blood pressure measurement to optimize hypertension care.
This paper reviews the manifestations and consequences of BP mismeasurement and misinterpretation in clinical practice and draw on recent research to propose a set of solutions that leverage available technologies to optimize hypertension care.
AHRQ-funded; HS024262.
Citation: Muldoon MF, Kronish IM, Shimbo D .
Of signal and noise: overcoming challenges in blood pressure measurement to optimize hypertension care.
Circ Cardiovasc Qual Outcomes 2018 May;11(5):e004543. doi: 10.1161/circoutcomes.117.004543..
Keywords: Blood Pressure, Diagnostic Safety and Quality, Adverse Events, Medical Errors, Electronic Health Records (EHRs), Health Information Technology (HIT), Quality of Care
Thomas HN, Evans GW, Berlowitz DR
Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT).
The researchers evaluated the relations among class of antihypertensive medication from women in the Systolic Blood Pressure Intervention Trial (SPRINT) and the outcomes: sexual activity and sexual function. There were no significant differences in sexual activity among women taking one or more antihypertensives and women not taking any. Women taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker had higher odds of sexual activity. The authors concluded that no single class of antihypertensive medication was associated with sexual dysfunction.
AHRQ-funded; HS022989.
Citation: Thomas HN, Evans GW, Berlowitz DR .
Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT).
J Hypertens 2016 Jun;34(6):1224-31. doi: 10.1097/hjh.0000000000000911.
.
.
Keywords: Medication, Blood Pressure, Sexual Health, Women, Adverse Drug Events (ADE), Adverse Events